Your browser doesn't support javascript.
loading
No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?
Sunakawa, Y; Tsuji, A; Fujii, M; Ichikawa, W.
Affiliation
  • Sunakawa Y; Division of Medical Oncology, Showa University Northern Yokohama Hospital, Tsuzuki-ku, Yokohama, Kanagawa.
  • Tsuji A; Department of Clinical Oncology, Kagawa University Faculty of Medicine Cancer Center, Kagawa University Hospital, Miki-cho, Kita-gun, Kagawa.
  • Fujii M; Department of Digestive Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo.
  • Ichikawa W; Division of Medical Oncology, Showa University Fujigaoka Hospital, Aoba-ku, Yokohama, Kanagawa, Japan.
Ann Oncol ; 28(8): 2030-2031, 2017 08 01.
Article in En | MEDLINE | ID: mdl-28475674
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Antineoplastic Combined Chemotherapy Protocols Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2017 Document type: Article Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Antineoplastic Combined Chemotherapy Protocols Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2017 Document type: Article Country of publication: United kingdom